Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B.
Pontes C, et al. Among authors: torrent farnell j.
Appl Health Econ Health Policy. 2020 Feb;18(1):5-16. doi: 10.1007/s40258-019-00527-x.
Appl Health Econ Health Policy. 2020.
PMID: 31696433
Free article.